{
    "nct_id": "NCT03388346",
    "official_title": "68Ga PSMA-HBED-CC in Intermediate to High-Risk Preprostatectomy Patients",
    "inclusion_criteria": "* Biopsy-proven prostate adenocarcinoma\n* Intermediate to high-risk disease, defined as one of the following factors: PSA > 10, T2b or greater, or a Gleason score of 7 or greater\n* A PSA level resulted within the past 2 months\n* Planned prostatectomy with lymph node dissection\n* Karnofsky performance status (KPS) greater than or equal to 50 (ECOG/WHO 0, 1, or 2) within the last 3 months\n* Must be treatment na√Øve (not have received neoadjuvant chemotherapy, radiation therapy, hormonal therapy, androgen deprivation therapy, or focal ablation techniques (e.g., HiFu)\n* Not receiving any other investigational agents (i.e., unlabeled drugs or drugs under an IND for initial efficacy investigations\n* Ability to understand and the willingness to provide informed consent.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Cannot receive furosemide\n* Allergy to sulfa or sulfa-containing medications\n* History of Stevens-Johnson syndrome\n* Known Paget's disease\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements",
    "miscellaneous_criteria": ""
}